NCT02452008
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 21 with changes below. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 6, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 23 words
- Secondary endpoints revised (3)
- Primary endpoint revised
- Publications: details revised at 1 of 1 entry
- Minor Primary completion date changed from estimate of Dec 2025 to Dec 8, 2025
- Study completion date: May 2026 to Dec 2026
- Notable Primary completion date: May 2025 to Dec 2025
- Collaborators: 1 to 2
- Notable Primary completion date: Oct 2024 to May 2025
- Study completion date: Dec 2025 to May 2026
- Notable Eligibility criteria expanded, about 7 words
- Trial status: Recruiting to Active, Not Recruiting
- Primary completion date: Jun 2024 to Oct 2024
- Site details revised at 4 of 4 sites
Show 15 earlier versionsHide 15 earlier versions
- Notable Primary completion date: Jun 2023 to Jun 2024
- Study completion date: Dec 2023 to Dec 2025
- Notable Primary completion date: Jun 2022 to Jun 2023
- Study completion date: Dec 2022 to Dec 2023
- Minor Primary completion date: Dec 2021 to Jun 2022v14
- Minor Site details revised at 1 of 4 sitesv13
- Minor Primary completion date: Jul 2021 to Dec 2021
- Study completion date: Jul 2021 to Dec 2022
- Notable Primary completion date: Jul 2020 to Jul 2021v11
- Notable Primary completion date: Jul 2019 to Jul 2020
- Start date: Apr 2016 to May 3, 2016
- Minor Collaborators expanded, about 4 wordsv9
- Minor Site details revised at 1 of 4 sitesv8
- Minor Study sites: 3 to 4v7
- Minor Study sites: 2 to 3v6
- Minor Study completion date: Jul 2021v5
- Notable Eligibility criteria expanded, about 6 wordsv4
- Minor Study sites: 1 to 2
- Study title expanded, about 1 word
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jul 2015 to Apr 2016
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression Free Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2) Using RECIST 1.1 Criteria.
Timeframe: 8 years
Secondary (3)
Number of Participants With (PSA50) Response
Overall Survival (OS) in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide and LY2157299 (Arm 1) Versus Enzalutamide Alone (Arm 2).
Number of Patients Experiencing Treatment-related Toxicities
Arms and interventions
Arm 1: Enzalutamide with LY2157299Experimental
Arm 2: Enzalutamide aloneExperimental
Drugs: Enzalutamide, LY2157299
Sites
4 sites in 1 country